Private Capital To Enter High-End Health Care Market
This article was originally published in PharmAsia News
San Paulo Mans Hospital, the first patient membership hospital in Beijing, has commenced operation, marking the beginning of private capital flowing into China's high-end health care market. Most analysts hold optimistic views about the development and point out that private investment in luxury health care will meet the requirements of a growing high-income market. As the government puts priority on supporting basic health care and providing insurance to its disadvantaged population, the latest involvement by the private sector frees it to focus on formulating regulations and standards, setting admittance thresholds, enhancing market supervision, providing reasonable subsidies and creating a fair competition environment for private capital. (Click here for more - Chinese Language)
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.